Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Feb;7(1):e001553.
doi: 10.1136/rmdopen-2020-001553.

Vaccination of patients with inflammatory rheumatic diseases against SARS-CoV-2: considerations before widespread availability of the vaccines

Hendrik Schulze-Koops  1 , Christof Specker  2 , Alla Skapenko  3
Affiliations
Review

Vaccination of patients with inflammatory rheumatic diseases against SARS-CoV-2: considerations before widespread availability of the vaccines

Hendrik Schulze-Koops et al. RMD Open. 2021 Feb.

Abstract

Vaccination against SARS-CoV-2 has become available and will hopefully end the current pandemic. Understandably, patients with inflammatory rheumatic diseases (iRMDs) and their physicians are feverishly preoccupied with questions about vaccination and the vaccines against SARS-CoV-2. However, as it will take months before all patients with iRMDs will have access to the vaccines, measures that are taken now in order to increase potential safety and efficacy of the vaccines may impose a risk for the patients with regard to reactivation of their underlying iRMD. The ad hoc commission 'Covid-19' and the board of directors of the German Society for Rheumatology have addressed this topic and have developed considerations, which are intended to answer urgent questions, to take away concerns and fears and to make initial recommendations for patients with iRMDs.

Keywords: COVID-19; inflammation; vaccination.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

References

    1. World Health Organization . WHO Director-General’s opening remarks at the media briefing on COVID-19 — 11 March 2020. Available: https://www.who.int/director-general/speeches/detail/who-director-genera...
    1. Walsh EE, Frenck RW, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med 2020;383:2439–50. 10.1056/NEJMoa2027906 - DOI - PMC - PubMed
    1. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med Overseas Ed 2020;383:2603–15. 10.1056/NEJMoa2034577 - DOI - PMC - PubMed
    1. Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA vaccine against SARS-CoV-2 — preliminary report. N Engl J Med 2020;383:1920–31. 10.1056/NEJMoa2022483 - DOI - PMC - PubMed
    1. Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 2021;397:99–111. 10.1016/S0140-6736(20)32661-1 - DOI - PMC - PubMed

Substances